ALGS drops 12.49% over 7 days amid optimism for HBV and MASH treatments
- Aligos Therapeutics (ALGS) saw a 12.49% 7-day stock decline despite positive HBV/MASH trial data. - Pevifoscorvir showed superior HBV DNA suppression and safety, with Phase II trials ongoing for 2026-2027 data. - ALG-009 demonstrated metabolic benefits for MASH, positioning Aligos as a key player in liver disease innovation. - Recent 23,600-share equity grants to new hires aim to strengthen R&D capabilities and operational growth.
As of November 17, 2025,
Encouraging Clinical Results for HBV and MASH
At the same time, Aligos shared advancements in its programs targeting MASH and obesity. ALG-009, another leading candidate, has demonstrated greater effectiveness and metabolic improvements, showing significant promise for treating metabolic dysfunction-associated steatohepatitis (MASH). These achievements indicate that the company is making substantial progress in addressing critical gaps in liver and viral disease treatments.
Focused R&D and Clinical Progress
Aligos bases its strategy on scientific innovation, building a pipeline aimed at challenging diseases such as HBV and MASH. During the recent conference, company leaders reiterated their dedication to creating top-tier therapies, highlighting their long-term goal of enhancing patient care through advanced medical solutions.
The company’s ongoing clinical work demonstrates its commitment to assembling a strong portfolio that targets persistent and widespread illnesses. With both Pevifoscorvir and ALG-009 actively being tested, Aligos is set to deliver important clinical data soon, which could impact investor confidence and the company’s market stance.
Stock Option Awards for Recent Employees
On November 14, 2025, Aligos revealed it had granted stock options under its 2024 Inducement Plan to new team members. These non-qualified options were provided to help attract and keep skilled professionals, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant covers 23,600 shares, with the exercise price matching the closing price on the grant date. Vesting will occur over four years, with 25% vesting each year and the remainder vesting monthly, contingent on continued employment.
This initiative highlights the company’s commitment to investing in its personnel, supporting its clinical ambitions, and enhancing operational strength. The equity awards are part of Aligos’ broader growth plan and its mission to bring innovative treatments to patients who need them most.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why Analysts Say Warren Buffett’s Japan Strategy May Indirectly Boost Ripple and XRP

XRP News Today: Despite Record Inflows into XRP ETF, Token Experiences 4.3% Decline
- XRP fell 4.3% to $2.22 despite Canary Capital's XRPC ETF securing $245M inflows, outperforming 2025 ETF peers. - Analysts cite delayed ETF settlement mechanics , macroeconomic pressures, and $28M in XRP liquidations as key price drivers. - XRPC's success contrasted with $866M Bitcoin ETF outflows, highlighting shifting institutional crypto preferences. - Experts predict gradual XRPC-driven demand but warn XRP remains vulnerable below critical $2.30 support level.

Ethereum Updates: As Bitcoin Faces Greater Market Challenges, Corporate Treasuries Shift Focus to Ethereum
- BitMine Immersion appoints Chi Tsang as CEO, now holding 3.5M ETH ($12.4B) as it shifts focus to Ethereum financial services. - Strategy's stock plummets below Bitcoin treasury value (mNAV 1.24), reflecting waning investor confidence despite Saylor's bullish stance. - Ethereum drops 5.46% amid $259M ETF outflows, while Bitcoin falls below $95K after $1.4B liquidation event. - Corporate treasuries expand beyond BTC/ETH, with Forward Industries (Solana) and Cypherpunk (Zcash) adopting new crypto strategies

The Rise of ICP Caffeine AI in Web3 Advancement: Evaluating the Investment Impact of AI-Powered Governance within Blockchain Networks
- ICP Caffeine AI, developed by Dfinity, enables no-code dApp creation via natural language, driving a 56% ICP token surge and $237B TVL by Q3 2025. - Despite growth, dApp usage fell 22.4%同期, exposing fragility in AI-driven ecosystems, while AI governance risks like model misalignment and bias threaten decentralization. - Strategic partnerships with Microsoft Azure and institutional investor appeal contrast with challenges in sustaining adoption and mitigating AI-related security incidents. - Experts advoc
